In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result

Gene

Volumn 518, Issue 1, 2013, Pages 201-208

  Yang, Wu Lung R ^a   Lee, Yu En ^b   Chen, Ming Huang ^b,c   Chao, Kun Mao ^a   Huang, Chi Ying F ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Drug screening; Hepatocellular carcinoma; Support Vector Machines

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ALEXIDINE; ALSTERPAULLONE; ALVESPIMYCIN; CALMIDAZOLIUM; CEPHAELINE; DIGITOXIGENIN; DIGOXIGENIN; DISULFIRAM; DOXORUBICIN; GELDANAMYCIN; HELVETICOSIDE; LANATOSIDE C; MITOXANTRONE; OUABAIN; PERHEXILINE; PRENYLAMINE; PROSCILLARIDIN; PUROMYCIN; RADICICOL; SANGUINARINE; SORAFENIB; STROPHANTHIDIN; SULOCTIDIL; TANESPIMYCIN; TERFENADINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; COMPUTER MODEL; CONNECTIVITY MAP; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; GADD45B GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; METALLOTHIONEIN IE; MICROARRAY ANALYSIS; ONCOGENE MYC; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMPUTER SIMULATION; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ROC CURVE; SUPPORT VECTOR MACHINES; TRANSCRIPTOME;

EID: 84875373574     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.11.030     Document Type: Article

References (36)

1. Abeel T., Helleputte T., Van de Peer Y., Dupont P., Saeys Y. Robust biomarker identification for cancer diagnosis with ensemble feature selection methods. Bioinformatics 2010, 26:392-398.
2. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 1995, 289-300.
3. Bleakley K., Yamanishi Y. Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 2009, 25:2397-2403.
4. Chen J., et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screen. 2003, 10:204-209.
5. Chen M.H., et al. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One 2011, 6:e27186.
6. Cheng A.L., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008, 10:25-34.
7. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
8. Datta J., et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007, 67:2736-2746.
9. Eckert H., Bajorath J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov. Today 2007, 12:225-233.
10. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
11. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
12. Gentleman R.C., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
13. Guyon I., Weston J., Barnhill S., Vapnik V. Gene selection for cancer classification using support vector machines. Mach. Learn. 2002, 46:389-422.
14. Hong F., Breitling R. A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 2008, 24:374-382.
15. Hsu C.N., et al. Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics 2007, 8:66.
16. Iorio F., et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14621-14626.
17. Iorio F., Rittman T., Ge H., Menden M., Saez-Rodriguez J. Transcriptional data: a new gateway to drug repositioning?. Drug Discov. Today 2012, Available online 6 August 2012, ISSN 1359-6446, 10.1016/j.drudis.2012.07.014.
18. Johannes M., Frohlich H., Sultmann H., Beissbarth T. pathClass: an R-package for integration of pathway knowledge into support vector machines for biomarker discovery. Bioinformatics 2011, 27:1442-1443.
19. Lamb J. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
20. Lin C.P., Liu C.R., Lee C.N., Chan T.S., Liu H.E. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J. Hepatol. 2010, 2:16-20.
21. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
22. Luo H., et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011, 39:W492-W498.
23. Martin J., Dufour J.F. Tumor suppressor and hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1720.
24. Nagamine N., et al. Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput. Biol. 2009, 5:e1000397.
25. Nakagawa S.I., Umehara T., Matsuda C., Kuge S., Sudoh M., Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun. 2007, 353:882-888.
26. Newman R.A., Yang P., Pawlus A.D., Block K.I. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv. 2008, 8:36-49.
27. Ou D.L., et al. Induction of DNA damage-inducible gene GADD45B contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010, 70:9309-9318.
28. Prassas I., Diamandis E.P. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 2008, 7:926-935.
29. Qiu W., Zhou B., Chu P.G., Luh F., Yen Y. The induction of growth arrest DNA damage-inducible gene 45 B in human hepatoma cell lines by S-adenosylmethionine. Am. J. Pathol. 2007, 171:287-296.
30. Qui W., David D., Zhou B. Down-regulation of growth arrest DNA damage-inducible gene 45B expression is associated with human hepatocellular carcinoma. Am. J. Pathol. 2003, 162:1961-1974.
31. R Development Core Team R: a language and environment for statistical computing 2011.
32. Senturk S., Mumcuoglu M., Gursoy-Yuzugullu O., Cingoz B., Akcali K.C., Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 2010, 52:966-974.
33. Subramanian A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15545-15550.
34. Varma S., Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 2006, 7:91.
35. Vilaseca J., Guardia J., Bacardí R., Monné J. Doxorubicin for liver cancer. Lancet 1978, 311:1367.
36. Yang H., Zhan Q., Wan Y.J.Y. Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. Hepatology 2011, 53:865-874.